企業を読み込み中
Just reported
Q3 2026 results
From Regeneron Pharmaceuticals's results release of 2026年10月30日; its quarterly report has since been filed.
Revenue
Actual
$5.12B
+36% y/y
+19% q/qGuided
—
No guide given
EPS, GAAP
Actual
$18.45
+35% y/y
+51% q/qGuided
—
No guide given
Operating income, GAAP
Actual
$2.05B
+99% y/y
+58% q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Regeneron Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.5BA+
EXELExelixis, Inc.$17BA+
JAZZJazz Pharmaceuticals plc$15.4BA
HALOHalozyme Therapeutics, Inc.$11.5BA+
TECHBIO-Techne Corp$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A
どうやって稼いでいるか
- Collaboration revenue47%
- Product revenue38%
- Libtayo net product sales11%
- Product and service other4%
- Lynozyfic0%
売上構成比はquarter ended March 31, 2026の推計であり、提出された報告書の数字ではありません。
競合
何を売っているか6
Dupixent
An injected medicine used for several allergic and inflammatory conditions, including eczema, asthma, and chronic obstructive pulmonary disease.
EYLEA HD
An injection into the eye for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.
EYLEA
An injection into the eye for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.
さらに3件を表示
Libtayo
An immune-system cancer medicine used for several cancers, including certain skin cancers and lung cancer.
Praluent
An injected medicine that lowers cholesterol and reduces cardiovascular risk in some patients.
Otarmeni
A gene therapy for hearing loss caused by changes in the otoferlin gene.
誰が買っているか2
- Drug wholesalers and specialty distributors buy medicines for supply to pharmacies, hospitals, and other healthcare providers.
- Pharmacies, hospitals, government agencies, physicians, and other healthcare providers buy or use Regeneron medicines for patients.
何に支えられ、何に崩されうるか
事業が頼っているもの
- 1A small number of customers together accounted for 77% (year ended December 31, 2025, high) of gross product revenue.
- 2Sales depend substantially on Dupixent, EYLEA HD, and EYLEA, and on continued commercial work with Sanofi and Bayer.
- 3Some medicines rely on single-source suppliers and on collaborators or contractors for filling, packaging, testing, and distribution.
- 4Sales depend on health insurers and government programs deciding whether to cover medicines and how much to reimburse.
うまくいかなくなる可能性
- 1EYLEA faces competition from other retinal medicines and biosimilars; the company has reported lower EYLEA sales as patients switch to EYLEA HD and other treatments compete for use.
- 2A large share of revenue depends on a few medicines and on partner arrangements, so lower sales, reduced reimbursement, or a change to a collaboration could materially affect revenue.
- 3Clinical studies can fail and regulators can delay or reject applications; recent examples include a fianlimab cancer study that missed its main goal and discontinued development of itepekimab in several respiratory conditions.
Regeneron Pharmaceuticals, Inc.について
Regeneron discovers, develops, makes, and sells medicines for conditions including eye diseases, allergic and inflammatory diseases, and cancer. Its medicines include Dupixent for inflammatory diseases, EYLEA for retinal conditions, and Libtayo for cancer. It sells some medicines itself and shares sales profits with partners such as Sanofi and Bayer, which also sell certain medicines.
- 本社
- Tarrytown, New York
- 設立
- 1988
- 上場市場
- NASDAQ
- 決算期
- December 31
Regeneron Pharmaceuticals, Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。